Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)
2012 ◽
Vol 48
(7)
◽
pp. 1023-1030
◽
2001 ◽
Vol 3
(2)
◽
pp. 65-70
◽
2010 ◽
Vol 16
(21)
◽
pp. 5320-5328
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 3516-3516
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 3516-3516
2009 ◽
Vol 27
(15_suppl)
◽
pp. e15032-e15032